Mustang说,数据显示总体缓解率为90%,有一名患者在31个月后完全缓解。所有参加研究的10名患者之前都接受过BTKi疗法的治疗。该公司补充说,根据一...查看全文
医药魔方06-20 10:41
6月17日,Mustang Bio公布的MB-106(一种靶向CD20的自体CAR-T细胞疗法)的I/II期临床试验数据显示,该疗法在华氏巨球蛋白血症(WM)患者中显示出良好的安全性和有效性。
MB-106由Mustang和Fred Hutch癌症中心合作开发,用于治疗复发或难治性B细胞非霍奇金淋巴瘤(B-NHL)和慢性淋巴细胞白血病...查看全文
Mustang Bio(MBIO)05-13 18:15
$Mustang Bio(MBIO)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001104659-24-060115 Act: 33 Size: 228 KB 网页链接查看全文
Mustang Bio(MBIO)05-02 05:05
$Mustang Bio(MBIO)$ 424B4 Prospectus [Rule 424(b)(4)] Accession Number: 0001104659-24-055793 Act: 33 Size: 380 KB 网页链接查看全文
Mustang Bio(MBIO)06-07 05:05
$Mustang Bio(MBIO)$ 8-K Current report, items 1.01, 1.02, and 9.01 Accession Number: 0001104659-24-069131 Act: 34 Size: 206 KB 网页链接查看全文
Mustang Bio(MBIO)06-29 04:25
$Mustang Bio(MBIO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-076298 Size: 5 KB 网页链接查看全文
Mustang Bio(MBIO)04-29 21:35
$Mustang Bio(MBIO)$ S-1/A [Amend] General form for registration of securities under the Securities Act of 1933 Accession Number: 0001104659-24-053575 Act: 33 Size: 1 MB 网页链接查看全文
医药魔方06-20 10:41
6月17日,Mustang Bio公布的MB-106(一种靶向CD20的自体CAR-T细胞疗法)的I/II期临床试验数据显示,该疗法在华氏巨球蛋白血症(WM)患者中显示出良好的安全性和有效性。
MB-106由Mustang和Fred Hutch癌症中心合作开发,用于治疗复发或难治性B细胞非霍奇金淋巴瘤(B-NHL)和慢性淋巴细胞白血病...查看全文
美股滚雪球06-18 11:31
$Mustang Bio(MBIO)$ 飙涨580%,公司公布了其CAR-T细胞疗法MB-106治疗华氏巨球蛋白血症(WM,一种非霍奇金淋巴瘤,或NHL)的1/2期试验的积极数据。
Mustang说,数据显示总体缓解率为90%,有一名患者在31个月后完全缓解。所有参加研究的10名患者之前都接受过BTKi疗法的治疗。该公司补充说,根据一...查看全文
产业链观察03-28 21:23
#药闻简讯# 2024年3月28日,专注于将当今细胞和基因疗法的医学突破转化为难以治疗的癌症和罕见遗传疾病的潜在治疗方法临床阶段的生物制药公司$Mustang Bio(MBIO)$ 宣布通过MB-106扩展到自身免疫性疾病,MB-106是一种个性化的CD20靶向第三代自体CAR T细胞疗法。MB-106 是 Mustang 和 Fred Hutchinso...查看全文
蓮花982023-06-17 01:15
$Mustang Bio(MBIO)$真的吗?
BTIG Maintains Buy on Mustang Bio, Raises Price Target to $20查看全文
蓮花982023-06-13 15:14
$Mustang Bio(MBIO)$ 嘩!In a report released today, Joseph Pantginis{Joseph Pantginis} from H.C. Wainwright reiterated a Buy rating on Mustang Bio, with a price target of $25.00. The company’s shares opened today at $6.46.查看全文
产业链观察2021-11-11 19:20
药闻▶2021年11月10日,专注于将当今细胞和基因疗法的医学突破转化为血液肿瘤、实体瘤和罕见遗传疾病的潜在治疗方法的临床阶段的生物制药公司$Mustang Bio(MBIO)$ 今天宣布公司已经与莱顿大学医学中心("LUMC")签署了一项独家许可协议,用于治疗RAG1严重联合免疫缺陷("...查看全文
$Mustang Bio(MBIO)$ 8-K - Current report Filed: 2019-05-10 AccNo: 0001144204-19-025070 Size: 88 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Mustang Bio(MBIO)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2019-05-01 AccNo: 0001144204-19-022960 Size: 402 KB 网页链接
$Mustang Bio(MBIO)$ DEF 14A - Other definitive proxy statements Filed: 2019-04-30 AccNo: 0001144204-19-022360 Size: 1 MB 网页链接
$Mustang Bio(MBIO)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-04-30 AccNo: 0001144204-19-022371 Size: 737 KB 网页链接
$Mustang Bio(MBIO)$ 8-K - Current report Filed: 2019-04-30 AccNo: 0001144204-19-022388 Size: 325 KBItem 1.01: Entry into a Material Definitive AgreementItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Mustang Bio(MBIO)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2019-04-29 AccNo: 0001144204-19-021930 Size: 401 KB 网页链接
$Mustang Bio(MBIO)$ 8-K - Current report Filed: 2019-04-04 AccNo: 0001144204-19-018182 Size: 651 KBItem 1.01: Entry into a Material Definitive AgreementItem 9.01: Financial Statements and Exhibits 网页链接
$Mustang Bio(MBIO)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2019-03-18 AccNo: 0001144204-19-014624 Size: 7 MB 网页链接
$Mustang Bio(MBIO)$ 8-K - Current report Filed: 2019-03-18 AccNo: 0001144204-19-014633 Size: 109 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$Mustang Bio, Inc.(MBIO)$ 8-K - Current report Filed: 2018-11-14 AccNo: 0001144204-18-059460 Size: 110 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接